A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Intrahepatic Cholangiocarcinoma (ICC)
DRUG: ICP-192
Objective response rate (ORR), Up to 3 years
Progression-free survival (PFS), Up to 3 years|Disease control rate (DCR), Up to 3 years|Duration of response (DOR), Up to 3 years|Time to response (TTR), Up to 3 years|Overall survival (OS), Up to 3 years|The adverse event (AE) of ICP-192 assessed by NCI-CTCAE V5.0, Up to 3 years|Maximum concentration (Cmax), Up to 3 years|Time to maximum concentration (Tmax), Up to 3 years|Half-life (T1/2), Up to 3 years|Area under the concentration-time curve (AUC), Up to 3 years|Apparent clearance (CL/F), Up to 3 years|Terminal apparent volume of distribution (Vz/F), Up to 3 years
To explore the relationship between blood phosphorus and clinical efficacy, Up to 3 years
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy